Showing 4471-4480 of 20465 results for "".
- Swiss Skincare Brand Launches Personalized Art of Longevity Programhttps://reachmd.com/news/swiss-skincare-brand-launches-personalized-art-of-longevity-program/2487890/Swiss skincare company Valmont has introduced The Art of Longevity, a personalized program designed to integrate genetic analysis, lifestyle assessment, and professional skincare into an individualized longevity strategy. According to the company, the initiative was developed by Valmont CE
- Biologic Strategies for Noninfectious Uveitis in a Randomized Trialhttps://reachmd.com/news/biologic-noninfectious-uveitis-randomized-trial/2487884/Key Takeaways Adalimumab and tocilizumab reached the week 16 corticosteroid-sparing endpoint at similar observed rates of 16% and 14%, respectively. Interim analyses found anakinra ineffective. Mild to moderate adverse events were reported in 43% and 5
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://reachmd.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned
- Diranersen Slows Decline in Phase 2 CELIA Trial for Early Alzheimer Diseasehttps://reachmd.com/news/diranersen-slows-decline-in-phase-2-celia-trial-for-early-alzheimer-disease/2487872/Key Takeaways After 18 months, diranersen was associated with less decline than placebo across the named clinical measures in early Alzheimer disease. The clinical signal was paired with a biomarker effect, and investigators described the result as ran
- Hugo Robotic Prostatectomy Trial Meets Safety And Effectiveness Endpointshttps://reachmd.com/news/hugo-robotic-prostatectomy-trial-meets-safety-and-effectiveness-endpoints/2487868/Key Takeaways Across the three included operations, prespecified safety and effectiveness endpoints were achieved. Effectiveness was defined by freedom from conversion, and safety by 30-day Clavien-Dindo Grade ≥III complications. Major complic
- GB-0669 Phase 1 Trial Reports Long Half-Life, Mild Adverse Reactionshttps://reachmd.com/news/gb-0669-phase-1-trial/2487862/Key Takeaways GB-0669 was well tolerated, with no dose-limiting toxicities and only mild adverse reactions. Exposure was dose-proportional up to 2400 mg, and the half-life was 54 days. Serum live virus neutralization increased at 600 mg and 12
- Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal Metastaseshttps://reachmd.com/news/perioperative-systemic-therapy-surgery-colorectal-peritoneal-metastases/2487859/Key Takeaways Investigators observed longer median overall survival with perioperative systemic therapy, but the survival comparison did not reach statistical significance. Safety findings included higher major postoperative morbidity after perioperati
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://reachmd.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- Dialectical Behavior Therapy vs Schema Therapy for Borderline Personality Disorderhttps://reachmd.com/news/dialectical-behavior-therapy-vs-schema-therapy-for-borderline-personality-disorder/2487840/Key Takeaways No statistically significant difference was observed between dialectical behavior therapy and schema therapy on the primary outcome. No significant between-group differences were reported on secondary outcomes, while both groups improved
- Biologic Therapies for Uncontrolled Asthma: Comparative Review Findingshttps://reachmd.com/news/biologic-therapies-for-uncontrolled-asthma-comparative-review-findings/2487841/Key Takeaways Indirect comparisons in severe uncontrolled asthma linked dupilumab and tezepelumab with more favorable annualized exacerbation outcomes than several comparator biologics. In eosinophilic asthma, mepolizumab, tezepelumab, and dupilumab sh